Goodman Corey S
SEC-identified person · CIK 1278411 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| ALX Oncology Holdings INC ALXO | Director | filed 2020–2026 |
| Artiva Biotherapeutics, Inc. ARTV | Officer | filed 2024–2024 |
| Rayzebio, Inc. RYZB | Officer | filed 2023–2023 |
| Ventyx Biosciences, Inc. VTYX | Officer | filed 2021–2022 |
| Elevation Oncology, Inc. ELEV | Officer | filed 2021–2022 |
| Checkmate Pharmaceuticals, Inc. CMPI | Officer | filed 2020–2022 |
| Metacrine, Inc. MTCR | Officer | filed 2020–2021 |
| IPI Legacy Liquidation Co IMPLQ | Officer | filed 2021–2021 |
| Akero Therapeutics, Inc. AKRO | Officer | filed 2019–2020 |
| Precision Biosciences INC DTIL | Officer | filed 2019–2019 |
| Pfizer INC pfe | Senior Vice President | filed 2007–2009 |
| Renovis INC RNVS | Director · President and CEO | filed 2006–2008 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.